Drug Approval | November 13, 2024
EMA grants GMP Certificate of compliance to CuraTeQ biosimilars’ Hyderabad facility
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%
Growth markets revenue increased by 44 YoY to Rs. 812 crore
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
The centre is equipped with the most modern tools and provides an environment soothing for all professionals and patients
Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years
The group plans to establish new hospitals in Kerala developing large health cities in Kochi and Kozhikode
Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
Subscribe To Our Newsletter & Stay Updated
